ArticleOncogene2003
Differential regulation of p63 and p73 expression.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Regulation of macrophage IFNγ-stimulated gene expression by the transcriptional coregulator CITED1.Journal of cell science · 2023Article
- Review
- Deregulation of the pRb-E2F4 axis alters epidermal homeostasis and favors tumor development.Oncotarget · 2016Article
- Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line.The Journal of biological chemistry · 2014Article
- Article
- ∆N-P63α and TA-P63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites.Oncotarget · 2014Article
- Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- FANCD2 activates transcription of TAp63 and suppresses tumorigenesis.Molecular cell · 2013Article
- TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression.Oncogene · 2011Article
- Essential roles of androgen signaling in Wolffian duct stabilization and epididymal cell differentiation.Endocrinology · 2011Article
- Transgenic and knockout mice models to reveal the functions of tumor suppressor genes.Clinical Medicine Insights. Oncology · 2011Article
- The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex.PloS one · 2010Article
- TAp63 is a transcriptional target of NF-kappaB.Journal of cellular biochemistry · 2010Article
- p73 is essential for vitamin D-mediated osteoblastic differentiation.Cell death and differentiation · 2010Article
- Article
- p63 and p73 in human cancer: defining the network.Oncogene · 2007Review
- TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53.Oncogene · 2006Article
- An autoregulatory loop directs the tissue-specific expression of p63 through a long-range evolutionarily conserved enhancer.Molecular and cellular biology · 2006Article
- Article
- Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63.Nucleic acids research · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two homologs of the tumor suppressor p53, named p63 and p73, are each expressed from at least two start sites of mRNA synthesis, yielding full-length, transactivating (TA) isoforms, and also aminoterminally truncated (DeltaN) isoforms that act as antagonists to p53. The expression of TAp73-transcripts is induced by E2F and negatively regulated by transforming growth factor beta (TGFbeta). The DeltaNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity. Here, we have analysed the expression of p63 in comparison with p73. In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels. Accordingly, the 3' promoter of p73, but not that of p63, was activated by p53 in reporter assays. DeltaNp73 mRNA and DeltaNp73 protein, but not the p63 gene products, also accumulated when HaCat cells (lacking functional p53) were grown to high density. TAp73, but not TAp63, expression was suppressed by TGFbeta in these cells, and the TAp73, but not the TAp63, promoter was induced by E2F-1. Thus, in contrast to the functional similarities of their respective products, the expression levels of p63 and p73 are regulated by different mechanisms. This might be responsible for the discordant biological roles of p63 and p73 in development, as well as their deviant expression characteristics in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.